BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han QY, Liu ZW. Current treatment of chronic hepatitis C in China: Dilemma and potential problems. World J Gastroenterol 2016; 22(19): 4615-4618 [PMID: 27217693 DOI: 10.3748/wjg.v22.i19.4615] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018;66:1742-50. [PMID: 29272349 DOI: 10.1093/cid/cix1106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
2 Su S, Fairley CK, Sasadeusz J, He J, Wei X, Zeng H, Jing J, Mao L, Chen X, Zhang L. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome. J Med Virol 2018;90:518-25. [PMID: 29091279 DOI: 10.1002/jmv.24988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. J Comp Eff Res 2018;7:785-95. [PMID: 29860879 DOI: 10.2217/cer-2018-0005] [Reference Citation Analysis]
4 Chen JH, Zeng Z, Zhang XX, Zhang Y, Zhang RW, Wang S, Wu CH, Yu M, Liu D, Xi HL, Zhou YX, An YY, Xu XY. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World J Gastroenterol 2017; 23(22): 4072-4079 [PMID: 28652660 DOI: 10.3748/wjg.v23.i22.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Liu J, Zhang Y, Wu B, Wang S, Bin-Chia Wu D, You R. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. Front Pharmacol 2021;12:717504. [PMID: 34721016 DOI: 10.3389/fphar.2021.717504] [Reference Citation Analysis]
6 Cao S, Liu F, Wang T, Tan Y, Liu S, Liu Y, Gao L, Chen L. New patterns emerge after a sustained increase in the incidence of hepatitis C virus infection from 2004 to 2017: a joinpoint regression analysis. Public Health 2019;170:49-56. [PMID: 30928613 DOI: 10.1016/j.puhe.2019.01.014] [Reference Citation Analysis]
7 Menezes EG, Coelho-Dos-Reis JG, Cardoso LM, Lopes-Ribeiro Á, Jonathan-Gonçalves J, Porto Gonçalves MT, Cambraia RD, Soares EB, Silva LD, Peruhype-Magalhães V, Rios M, Chancey C, Teixeira-Carvalho A, Martins-Filho OA, Teixeira R. Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases. Antiviral Res 2017;141:19-28. [PMID: 28163109 DOI: 10.1016/j.antiviral.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]